CytoDyn Inc (CYDY:OTC) Annual Reports & Investor Relations Material

Overview

CytoDyn Inc. - a clinical-stage biotechnology company- is leading the way in developing innovative treatments for a range of therapeutic indications. The company's primary focus is on utilizing its groundbreaking novel humanized monoclonal antibody leronlimab to develop treatments for human immunodeficiency virus (HIV), non-alcoholic steatohepatitis (NASH), oncology, and even coronavirus disease (COVID-19). As part of its efforts, the company is conducting a Phase 1b/2 clinical trial to assess the efficacy of leronlimab in treating metastatic triple-negative breast cancer. CytoDyn Inc., which was previously known as RexRay Corporation, was established in 2002 and is headquartered in Vancouver, Washington.

Frequently Asked Questions

What is CytoDyn Inc's ticker?

CytoDyn Inc's ticker is CYDY

What exchange is CytoDyn Inc traded on?

The company's shares trade on the OTC stock exchange

Where are CytoDyn Inc's headquarters?

They are based in Vancouver, Washington

How many employees does CytoDyn Inc have?

There are 11-50 employees working at CytoDyn Inc

What is CytoDyn Inc's website?

It is https://www.cytodyn.com/

What type of sector is CytoDyn Inc?

CytoDyn Inc is in the Healthcare sector

What type of industry is CytoDyn Inc?

CytoDyn Inc is in the Biotechnology industry

Who are CytoDyn Inc's peers and competitors?

The following five companies are CytoDyn Inc's industry peers:

- Aileron Therapeutics, Inc.

- Chimerix

- Biofrontera AG

- AnPac Bio-Medical Science Co., Ltd.

- Regulus Therapeutics Inc